Polycythemia vera (PV) is a rare blood cancer causing the bone marrow to make too many blood cells. Treatment usually starts with phlebotomy and may continue with medications. If one treatment isn’t ...

Patients diagnosed with polycythemia vera currently have more specialized treatment options that may lead to improved responses to therapy, an expert said. Dr. Jamile M. Shammo, professor of medicine ...

Polycythemia vera (PV), which is marked by an increased number of red blood cells, is a rare blood cancer known to be associated with a high risk of cardiovascular disease. Median survival is ...

panelist discusses how polycythemia vera (PV) treatment approaches include both therapeutic phlebotomy and medications like hydroxyurea or interferon to control blood counts, with treatment selection ...

A breakthrough in the treatment of polycythemia vera, a rare and life-threatening blood cancer, has emerged with the introduction of a new drug named rusfertide. Polycythemia vera falls under the ...

NEWARK, Calif., June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG ...

The current treatment landscape of polycycthemia vera (PV) hinges on treatments like hydroxyurea and ruxolitinib, the latter having emerged as an effective second-line therapy in patients with severe ...

Protagonist Therapeutics, Inc. is progressing with the use of its drug rusfertide for the treatment of polycythemia vera in a phase 3 study. The company expects to complete enrollment of the VERIFY ...

Lipid Profiles Improved in Past Two Decades in United States For patients with polycythemia vera, more intense treatment to achieve a hematocrit target of (HealthDay News) – For patients with ...

The FDA approved ropeginterferon alfa-2b-njft for the treatment of adults with polycythemia vera. Ropeginterferon alfa-2b-njft (Besremi, PharmaEssentia) is a monopegylated, long-acting interferon.

Breakthrough designation for rusfertide was supported by positive 32-week data from the Phase 3 VERIFY study, which was presented as a late breaking abstract highlighting its practice-changing ...

Polycythemia Vera Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. report ...